The short version of circadian rhythm fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-23. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
US575002A patent on 01.Dec.1897 to Alexander Lodyguine (Lodygin, Russia) describes filaments made of rare metals, amongst them was tungsten. Lodygin invented a process where rare metals such as tungsten can be chemically treated and heat-vaporized onto an electrically heated thread-like wire (platinum, carbon, gold) acting as a temporary base or skeletal form. (US patent 575,002). Lodygin later sold the patent rights to General Electric. In 1902, Siemens developed a tantalum lamp filament that was more efficient than even graphitized carbon filaments since they could operate at higher temperature. Since tantalum metal has a lower resistivity than carbon, the tantalum lamp filament was quite long and required multiple internal supports. The metal filament gradually shortened in use; the filaments were installed with large slack loops. Lamps used for several hundred hours became quite fragile. Metal filaments had the property of breaking and re-welding, though this would usually decrease resistance and shorten the life of the filament. General Electric bought the rights to use tantalum filaments and produced them in the US until 1913. From 1898 to around 1905, osmium was also used as a filament in lamps made by Carl Auer von Welsbach. The metal was so expensive that used lamps could be returned for partial credit. It could not be made for 110 V or 220 V so several lamps were wired in series for use on standard voltage circuits. These were primarily sold in Europe.
In his public letter of resignation, he cited his reasons as being the lack of "the possibility of fulfilling, with the necessary total transparency, autonomy, and freedom, what Cuban Masonic legislation defines as required to carry out this responsibility." Alfonso Vidal said that the Grand Lodge was in the practice of "distorting Masonic Law." He also noted that because he had signed Decree 634, it was virtually impossible for him to have abandoned his post. He wrote that he was aware that he had been wrongfully terminated through an Extraordinary Session of the Supreme Court of Masonic Justice, and that those who signed his tacit resignation were being ordered to do so by the State Security Unit. He lamented the nature of the "...political gangsterism that works in the Grand Lodge of Cuba." Alfonso Vidal wrote that: "Cuban Masons have the right to know that our institution is under one of the greatest attacks it has received since January 1, 1959." He called back on the events surrounding the case of Grand Commander Viñas Alonso, and the letter that Viñas Alonso had sent to President Díaz-Canel. He said that the situation since Díaz-Canel had sent the State Security Unit after Viñas Alonso, the situation in Cuban Freemasonry had become increasingly difficult to operate within as an ethical and moral Grand Master. He could not fulfill his obligations as Grand Master for the fear of what actions the Cuban state might take against him. He also urged Cuban Freemasons to reject anyone from the Cuban intelligence community to ever again gain high office in the Grand Lodge.
=== Risk factors === There are over 100 risk factors for pressure ulcers. Factors that may place a patient at risk include immobility, diabetes mellitus, peripheral vascular disease, malnutrition, cerebral vascular accident and hypotension. Other factors are age of 70 years and older, current smoking history, dry skin, low body mass index, urinary and fecal incontinence, physical restraints, malignancy, vasopressin prescription, and history of prior pressure injury development.
Singapore and Sri Lanka. ISCEA's Certified Lean Master (CLM) programme is delivered in Hong Kong and Malaysia through SGS, the global inspection, verification, testing and certification entity. In 2019 Tim Charlton was appointed to the position of President of ISCEA-Pacific (Australia and New Zealand) and also appointed to the ISCEA- APAC Board that included Mr. Ejazur Rahman (Bangladesh) CEO, ISCEA-Asia, Mr. Nikhil Oswal (India), CEO, ISCEA-India, Dr. Premkumar Rajagopal (Malaysia), President, MUST (Malaysia University of Science and Technology), Mr. Sandeep Chatterjee (India), Senior Manager, Deloitte India, Dr. Nyoman Pujawan, Ph.D., (Indonesia), Professor, Institut Teknologi Sepuluh Nopember, and Dr. Harish Pant (India), Chief Business Transformation Officer, NTF (India) Pvt. Ltd. In 2024, ISCEA started a partnership with Singapore-based SCALA - Supply Chain and Logistics Academy. SCALA (Singapore) and PPLC Superport & Industrial Co., LTD. (Cambodia) signed a historic Memorandum of Understanding (MoU) to train up to 300 Cambodian trainees in Singapore. The training included hands-on experiential learning and certification as Certified Supply Chain Analysts from ISCEA. The MoU signing was further marked at the Cambodia-Singapore Business Forum in the presence of Samdech Moha Borvor Thipadei Hun Manet, Prime Minister of the Kingdom of Cambodia.
Sources: en.wikipedia.org
=== Red flags === Imaging is not typically needed in the initial diagnosis or treatment of back pain. However, if there are certain "red flag" symptoms present, plain radiographs (X-ray), CT scan or magnetic resonance imaging may be recommended. These red flags include:
AB + e− → A− + B+ + e− Calibration of the mass spectrometer is important in electron capture ionization mode. A calibration compound is needed to ensure reproducibility in EC-MS. It is used to ensure that the mass scale used is correct and that the groups of ions are constant on a regular basis. Fragmentation in ECI has been studied by tandem mass spectrometry. The technique can be used with gas chromatography-mass spectrometry.
== Transport == Fish is transported widely in ships, and by land and air, and much fish is traded internationally. It is traded live, fresh, frozen, cured and canned. Live, fresh and frozen fish need special care.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.